PE20150724A1 - Inhibidores de dgat1 de eter ciclico de cabeza de puente - Google Patents
Inhibidores de dgat1 de eter ciclico de cabeza de puenteInfo
- Publication number
- PE20150724A1 PE20150724A1 PE2014001902A PE2014001902A PE20150724A1 PE 20150724 A1 PE20150724 A1 PE 20150724A1 PE 2014001902 A PE2014001902 A PE 2014001902A PE 2014001902 A PE2014001902 A PE 2014001902A PE 20150724 A1 PE20150724 A1 PE 20150724A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclic ether
- bridge head
- dgat1 inhibitors
- treatment
- dgat1
- Prior art date
Links
- 229940127193 DGAT1 inhibitor Drugs 0.000 title 1
- 150000004292 cyclic ethers Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 101000785223 Crocosmia x crocosmiiflora Myricetin 3-O-glucosyl 1,2-rhamnoside 6'-O-caffeoyltransferase AT1 Proteins 0.000 abstract 1
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 abstract 1
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion se refiere a los compuestos de la formula (I), donde p es 1, 2 o 3; X es O o CH2; Y es O, CH2 o esta ausente; Z1, Z2, Z3 y Z4 son cada independientemente N o CH; A es entre otros oxazol, tiazol; utiles para el tratamiento de los trastornos mediados por acil-transferasa de acil-CoA-diacil-glicerol 1 (DGAT1), por ejemplo, los trastornos metabolicos. La invencion tambien proporciona metodos para el tratamiento de los trastornos, y las composiciones para su tratamiento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639341P | 2012-04-27 | 2012-04-27 | |
| US201361787695P | 2013-03-15 | 2013-03-15 | |
| CN2013072735 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150724A1 true PE20150724A1 (es) | 2015-05-17 |
Family
ID=48577190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001902A PE20150724A1 (es) | 2012-04-27 | 2013-04-25 | Inhibidores de dgat1 de eter ciclico de cabeza de puente |
| PE2016000359A PE20160802A1 (es) | 2012-04-27 | 2013-04-25 | Inhibidores de dgat1 de eter ciclico de cabeza de puente |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000359A PE20160802A1 (es) | 2012-04-27 | 2013-04-25 | Inhibidores de dgat1 de eter ciclico de cabeza de puente |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8993619B2 (es) |
| EP (1) | EP2852590B1 (es) |
| JP (1) | JP6042529B2 (es) |
| KR (1) | KR20150013194A (es) |
| CN (1) | CN104395309B (es) |
| AP (1) | AP3592A (es) |
| AR (1) | AR090859A1 (es) |
| AU (1) | AU2013254307B2 (es) |
| BR (1) | BR112014026760A8 (es) |
| CA (1) | CA2870336A1 (es) |
| CL (1) | CL2014002822A1 (es) |
| CO (1) | CO7111275A2 (es) |
| CR (1) | CR20140494A (es) |
| EA (1) | EA025050B1 (es) |
| EC (1) | ECSP14030538A (es) |
| ES (1) | ES2624291T3 (es) |
| IL (1) | IL235313A0 (es) |
| MA (1) | MA37439B1 (es) |
| MX (1) | MX357768B (es) |
| PE (2) | PE20150724A1 (es) |
| PH (1) | PH12014502413A1 (es) |
| SG (1) | SG11201406526WA (es) |
| TN (1) | TN2014000425A1 (es) |
| TW (1) | TW201348239A (es) |
| UY (1) | UY34767A (es) |
| WO (1) | WO2013160873A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583218B (zh) | 2012-04-26 | 2018-04-24 | 百时美施贵宝公司 | 作为蛋白酶活化受体4(par4)抑制剂用于治疗血小板聚集的咪唑并噻二唑和咪唑并吡嗪的衍生物 |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| PT2945939T (pt) | 2013-01-15 | 2020-06-08 | Incyte Holdings Corp | Compostos tiazole e piridina carboxamidas úteis como inibidores das quinases pim |
| US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| CN104292190B (zh) * | 2014-09-03 | 2016-05-04 | 哈尔滨工业大学 | 一种β-溴代四氢呋喃类化合物的合成方法 |
| CN104292189B (zh) * | 2014-09-03 | 2016-05-04 | 哈尔滨工业大学 | 一种β-丙二酸二乙酯取代四氢呋喃类化合物的合成方法 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| CN113366000A (zh) * | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP4637843B2 (ja) | 2003-05-20 | 2011-02-23 | ノバルティス アーゲー | ペルオキシソーム増殖因子活性化受容体のリガンドとしてのｎ−アシル窒素ヘテロ環 |
| WO2006017542A1 (en) * | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| SG10201408806UA (en) * | 2006-03-31 | 2015-02-27 | Novartis Ag | New compounds |
| ES2535083T3 (es) * | 2007-12-20 | 2015-05-05 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores 190 de DGAT1 |
| PT2781516T (pt) * | 2010-10-07 | 2017-03-15 | Novartis Ag | Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético |
| US8962660B2 (en) * | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
-
2013
- 2013-04-25 BR BR112014026760A patent/BR112014026760A8/pt not_active Application Discontinuation
- 2013-04-25 KR KR1020147032910A patent/KR20150013194A/ko not_active Ceased
- 2013-04-25 WO PCT/IB2013/053292 patent/WO2013160873A1/en not_active Ceased
- 2013-04-25 CN CN201380034256.8A patent/CN104395309B/zh not_active Expired - Fee Related
- 2013-04-25 AU AU2013254307A patent/AU2013254307B2/en not_active Ceased
- 2013-04-25 ES ES13727385.0T patent/ES2624291T3/es active Active
- 2013-04-25 EA EA201491970A patent/EA025050B1/ru not_active IP Right Cessation
- 2013-04-25 SG SG11201406526WA patent/SG11201406526WA/en unknown
- 2013-04-25 MA MA37439A patent/MA37439B1/fr unknown
- 2013-04-25 EP EP13727385.0A patent/EP2852590B1/en not_active Not-in-force
- 2013-04-25 PE PE2014001902A patent/PE20150724A1/es not_active Application Discontinuation
- 2013-04-25 AP AP2014008018A patent/AP3592A/xx active
- 2013-04-25 CA CA2870336A patent/CA2870336A1/en not_active Abandoned
- 2013-04-25 MX MX2014013002A patent/MX357768B/es active IP Right Grant
- 2013-04-25 JP JP2015507656A patent/JP6042529B2/ja not_active Expired - Fee Related
- 2013-04-25 PE PE2016000359A patent/PE20160802A1/es not_active Application Discontinuation
- 2013-04-26 AR ARP130101409A patent/AR090859A1/es unknown
- 2013-04-26 US US13/871,586 patent/US8993619B2/en not_active Expired - Fee Related
- 2013-04-26 TW TW102115141A patent/TW201348239A/zh unknown
- 2013-04-26 UY UY0001034767A patent/UY34767A/es not_active Application Discontinuation
-
2014
- 2014-10-13 TN TN2014000425A patent/TN2014000425A1/fr unknown
- 2014-10-20 CL CL2014002822A patent/CL2014002822A1/es unknown
- 2014-10-23 IL IL235313A patent/IL235313A0/en unknown
- 2014-10-27 PH PH12014502413A patent/PH12014502413A1/en unknown
- 2014-10-27 CR CR20140494A patent/CR20140494A/es unknown
- 2014-10-27 CO CO14237492A patent/CO7111275A2/es active IP Right Grant
- 2014-11-27 EC ECIEPI201430538A patent/ECSP14030538A/es unknown
-
2015
- 2015-02-20 US US14/628,205 patent/US20150166563A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150724A1 (es) | Inhibidores de dgat1 de eter ciclico de cabeza de puente | |
| PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| CL2019003747A1 (es) | Amidas heterocíclicas de 5 miembros y bicíclicas como inhibidores de rock. | |
| AR082112A1 (es) | Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica | |
| BR112015004111A2 (pt) | novos derivados bicíclicos | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| UY35700A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| AR072373A1 (es) | Tiadiazoliloxifenilamidinas, el uso de las mismas como fungicidas en composiciones y metodos de uso, proceso para su preparacion e intermediarios de sus sintesis. | |
| CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR067779A1 (es) | Profarmacos dipeptoides y su uso | |
| PE20161368A1 (es) | Inhibidores de diacilglicerol aciltranferasa 2 | |
| CR20140133A (es) | Compuestos de piridazinona y sus usos como inhibidores de daao | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| UY32004A (es) | Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| EA201990362A1 (ru) | Аналог вортиоксетина и его применение и получение | |
| PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
| UY32246A (es) | Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica | |
| BR112018013429A2 (pt) | ?composto, composição, método para o controle de um nematoide, utilização de uma composição e semente? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |